Recent trends in antipsychotic combination therapy of schizophrenia and schizoaffective disorder: Implications for state mental health policy

Schizophrenia Bulletin

Volumn 28, Issue 1, 2002, Pages 75-84

  Clark, Robin E ^a   Bartels, Stephen J ^a   Mellman, Thomas A ^a   Peacock, William J ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

Atypical antipsychotics; Combination therapy; Polypharmacy; Schizoaffective; Schizophrenia

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; CHLORPROMAZINE; CLONAZEPAM; CLOZAPINE; FLUPHENAZINE; GABAPENTIN; HALOPERIDOL; LAMOTRIGINE; LITHIUM; LORAZEPAM; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; TOPIRAMATE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIFLUOPERAZINE; VALPROIC ACID; VENLAFAXINE;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; FEMALE; HEALTH CARE COST; HEALTH CARE POLICY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAID; MEDICAL DECISION MAKING; MEDICAL PRACTICE; MENTAL HEALTH; POLYPHARMACY; PRESCRIPTION; PRIORITY JOURNAL; SCHIZOIDISM; SCHIZOPHRENIA; CLINICAL PATHWAY; DRUG COMBINATION; DRUG UTILIZATION; FORECASTING; MIDDLE AGED; PSYCHOLOGICAL ASPECT; PSYCHOLOGY; PSYCHOSIS; TREATMENT OUTCOME; UNITED STATES;

ADULT; ANTIPSYCHOTIC AGENTS; COHORT STUDIES; CRITICAL PATHWAYS; DRUG THERAPY, COMBINATION; DRUG UTILIZATION; FEMALE; FORECASTING; HEALTH POLICY; HUMANS; MALE; MEDICAID; MIDDLE AGED; NEW HAMPSHIRE; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 0035988519     PISSN: 05867614     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.schbul.a006928     Document Type: Article

References (39)

1. Combining risperidone with standard neuroleptics for refractory schizophrenic patients
2. Role of antipsychotic polypharmacotherapy in the treatment of schizophrenia
3. Possible effects of combining phenothiazines
4. Changing physician performance: A systematic review of the effect of continuing medical education strategies
5. Pharmacological and pharmakokinetic considerations in choosing an antipsychotic
6. Cost-effectiveness of clozapine compared with traditional antipsychotic medication for patients in State hospitals
7. Atypical antipsychotics in the treatment of schizophrenia: Systematic overview and meta-regression analysis
8. Multiple versus single antipsychotic drug treatment in psychosis
9. Concomitant use of thioridazine with risperidone
10. Effect of clinical guidelines on medical practice: A systematic review of rigorous evaluations
11. Olanzapine augmentation of clozapine
12. Risperidone as an adjunct to clozapine therapy in chronic schizophrenics
13. Efficacy of nurse telehealth care and peer support in augmenting treatment of depression in primary care
14. Randomized trial of a depression management program in high utilizers of medical care
15. The efficacy of atypical antipsychotics in the treatment of depressive symptoms, hostility and suicidality in patients with schizophrenia
16. Patterns of usual care for schizophrenia: Initial results from the Schizophrenia Patient Outcomes Research Team client survey
17. The role of the primary care physician in patients' adherence to antidepressant therapy
18. Use of sodium valproate in violent and aggressive behaviors: A critical review
19. Antipsychotic prescription use and costs for persons with schizophrenia in the 1990s: Current trends and five year time series forecasts
20. Risperidone augmentation of clozapine
21. Combining antipsychotics: Is there evidence for efficacy?
22. Risperidone and clozapine combination for the treatment of refractory schizophrenia
23. No magic bullets: A systematic review of 102 trials of interventions to improve professional practice
24. Effective educational techniques for primary care providers: Application to the management of psychiatric disorders
25. Clozapine and risperidone: Combination/augmentation treatment of refractory schizophrenia: A preliminary observation
26. The new atypical antipsychotics: A review of pharmacoeconomic studies
27. Multiple outcome assessment in a study of cost-effectiveness of clozapine in the treatment of refractory schizophrenia
28. Interview of S.M. Stahl in "Use caution when combining antipsychotics."
29. Sulpiride augmentation in people with schizophrenia partially responsive to clozapine: A doubleblind, placebo-controlled study
30. Randomised trial of monitoring, feedback, and management of care by telephone to improve treatment of depression in primary care
31. Depression in schizophrenia: Perspective in the era of "atypical" antipsychotic agents
32. Principles and uses of academic detailing to improve the management of psychiatric disorders
33. Effects of a limit on Medicaid drug-reimbursement benefits on the use of psychotropic agents and acute mental health services by patients with schizophrenia
34. Effects of Medicaid drug-payment limits on admission to hospitals and nursing homes
35. Selecting an atypical antipsychotic by combining clinical experience with guidelines from clinical trials
36. Antipsychotic polypharmacy, Part 1: Therapeutic option or dirty little secret?
37. Treatment of schizophrenia with antipsychotics in combination
38. Impact of disseminating quality improvement programs for depression in managed priary care
39. Pharmacoeconomics of the new antipsychotics for the treatment of schizophrenia